Leap Therapeutic SEC Filings

Leap Therapeutics called a virtual special meeting for December 15, 2025 to vote on five proposals tied to its recent financing and listing plans. The Board seeks to increase authorized shares to 500,000,000 (of which 490,000,000 would be common) and to authorize a reverse stock split within a 1:5 to 1:20 range to help regain Nasdaq minimum bid compliance.

Stockholders will also consider a new 2025 Equity Incentive Plan authorizing 22,500,000 shares (plus carryover from prior plans), and approval to issue shares above 19.99% of outstanding common upon warrant exercise from the October 2025 private placement—up to 152,754,109 shares under Nasdaq rules. An adjournment proposal is included.

In the October 2025 financing, Leap raised $58,888,888 in gross proceeds, issuing 15,212,311 shares and pre-funded warrants for 80,768,504 shares. Shares outstanding were 56,651,840 as of October 24, 2025. The Board unanimously recommends voting FOR all proposals.

Leap Therapeutics (LPTX) called a special stockholder meeting to vote on five proposals tied to its recent financing and listing compliance plans. The company completed a private placement for aggregate gross proceeds of $58,888,888, issuing 15,212,311 common shares, Pre-Funded Warrants for up to 80,768,504 shares, and Common Warrants for up to 71,985,605 shares at an exercise price of $0.5335 per share.

Stockholders will vote on: increasing authorized shares to 500,000,000 (490,000,000 common); authorizing a reverse stock split within a 1:5 to 1:20 range to help regain Nasdaq bid-price compliance; adopting the 2025 Equity Incentive Plan; and permitting issuance above 19.99% upon warrant exercise under Nasdaq rules, covering up to 152,754,109 shares. As of October 24, 2025, shares outstanding were 56,651,840. The company states proceeds support a digital asset treasury strategy and ongoing programs including FL-501 and sirexatamab.

Leap Therapeutics, Inc. filed an 8-K reporting a material event that attaches a resale registration statement and related agreements and exhibits. The filing specifies that the Resale Registration Statement must be kept continuously effective from the SEC effectiveness date until either the purchasers have resold all registrable securities or those securities become freely tradable under Rule 144 without volume or manner-of-sale limits and without reliance on the current public information requirement. The filing includes forms for a Common Warrant, Pre-Funded Warrant, a Securities Purchase Agreement, a Registration Rights Agreement, a Lead Investor Agreement, and a Press Release dated October 9, 2025. The document notes procedural timing tied to SEC operations (effectiveness timing can extend if the SEC is closed).

Schedule 13G/A disclosure for Leap Therapeutics, Inc. (LPTX) This filing is a joint Schedule 13G/A by Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju reporting that, as of June 30, 2025, each Reporting Person beneficially owns 0 shares (0.0%) of Leap Therapeutics common stock (CUSIP 52187K200). The Reporting Persons state they are not a "group" and provide a Palo Alto business address for the filer. The filing incorporates a prior Joint Filing Statement by reference and is signed by Srinivas Akkaraju on behalf of the entities on August 14, 2025. The statement certifies the securities were not acquired to influence control of the issuer.

Leap Therapeutics, Inc. (LPTX) filed a Form 8-K reporting an item related to Results of Operations and Financial Condition and furnished a press release as an exhibit. The filing identifies Item 9.01 (Financial Statements and Exhibits) and lists Exhibit 99.1 as a press release dated August 14, 2025. The disclosure is signed by Douglas E. Onsi, Chief Executive Officer and President. The document does not include financial statements, earnings figures, transaction details, or other substantive operational data within the provided text.

Leap Therapeutics reported a difficult quarter marked by clinical progress on its lead asset but acute financial stress. Updated DeFianCe Part B data showed sirexatamab (DKN-01) produced a statistically significant benefit on overall response rate and progression-free survival in colorectal cancer patients with high DKK1, no prior anti‑VEGF therapy, or liver metastasis, with final study results being prepared for conference presentation.

Financially, the company had $18.13 million in cash and cash equivalents and $20.04 million total assets as of June 30, 2025, and reported a $32.08 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $499.45 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern, implemented a workforce reduction of approximately 75% and recorded $4.53 million of restructuring charges, and engaged Raymond James to explore strategic alternatives.